This is the authors' abstract. We don't add key points for this paper.
From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-anti-rheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: